

Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/CD280B6E69BBEN.html

Date: November 2019

Pages: 52

Price: US\$ 125.00 (Single User License)

ID: CD280B6E69BBEN

Abstracts

Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Correvio Pharma Corp (Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company's product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). It has collaborations with other pharmaceutical companies to commercialize products which include Zevtera, a cephalosporin antibiotic indicated for the treatment of community and hospital acquired pneumonia and Xydalba, a second generation semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections. Correvio's pipeline product includes Trevyent a drug device combination for pulmonary arterial hypertension. The company has offices in Canada, the US, Switzerland, France and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.

Correvio Pharma Corp Key Recent Developments

Nov 14,2019: Correvio reports third quarter 2019 financial results

Aug 14,2019: Correvio reports second quarter 2019 financial results



May 08,2019: Correvio reports first quarter 2019 financial results

Mar 13,2019: Correvio reports fourth quarter and full year 2018 financial results

Jan 02,2019: Correvio announces chief executive officer succession plan and other

board and executive changes

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Correvio Pharma Corp - Key Facts

Correvio Pharma Corp - Key Employees

Correvio Pharma Corp - Key Employee Biographies

Correvio Pharma Corp - Major Products and Services

Correvio Pharma Corp - History

Correvio Pharma Corp - Company Statement

Correvio Pharma Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Correvio Pharma Corp - Business Description

Correvio Pharma Corp - SWOT Analysis

SWOT Analysis - Overview

Correvio Pharma Corp - Strengths

Correvio Pharma Corp - Weaknesses

Correvio Pharma Corp - Opportunities

Correvio Pharma Corp - Threats

Correvio Pharma Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019



Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Correvio Pharma Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Nov 14, 2019: Correvio reports third quarter 2019 financial results

Aug 14, 2019: Correvio reports second quarter 2019 financial results

May 08, 2019: Correvio reports first quarter 2019 financial results

Mar 13, 2019: Correvio reports fourth quarter and full year 2018 financial results

Jan 02, 2019: Correvio announces chief executive officer succession plan and other board and executive changes

Aug 14, 2018: Correvio announces second quarter 2018 financial results

May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV

May 15, 2018: Correvio Announces First Quarter 2018 Financial Results

May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of

Shareholders and Timing For First Quarter 2018 Financial Results Conference Call

Apr 06, 2018: Cardiome Announces Amendment To Term Loan Agreement With Crg-Managed Funds

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Correvio Pharma Corp, Key Facts

Correvio Pharma Corp, Key Employees

Correvio Pharma Corp, Key Employee Biographies

Correvio Pharma Corp, Major Products and Services

Correvio Pharma Corp, History

Correvio Pharma Corp, Subsidiaries

Correvio Pharma Corp, Key Competitors

Correvio Pharma Corp, Ratios based on current share price

Correvio Pharma Corp, Annual Ratios

Correvio Pharma Corp, Annual Ratios (Cont...1)

Correvio Pharma Corp, Annual Ratios (Cont...2)

Correvio Pharma Corp, Interim Ratios

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Correvio Pharma Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Correvio Pharma Corp, Performance Chart (2014 - 2018)

Correvio Pharma Corp, Ratio Charts

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2010

Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Sanofi-Aventis Canada Inc H. Lundbeck AS Gilead Sciences Inc AstraZeneca Canada Inc ASKA Research



I would like to order

Product name: Correvio Pharma Corp (CORV) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/CD280B6E69BBEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/CD280B6E69BBEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970